INVIVYD INC. - COMMON

0.8359

14-May-25 15:00:10

15 minutes delayed

Stocks

-0.0250

-2.90%

Today's range

0.7501 - 0.9200

ISIN

N/A

Source

NASDAQ

Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant

14 Dec 2021 06:00:00 By Nasdaq GlobeNewswire
Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

29 Nov 2021 05:30:00 By Nasdaq GlobeNewswire
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19

22 Nov 2021 05:30:00 By Nasdaq GlobeNewswire
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results

15 Nov 2021 05:30:00 By Nasdaq GlobeNewswire
Adagio Therapeutics to Participate in Upcoming Investor Conferences

10 Nov 2021 05:30:00 By Nasdaq GlobeNewswire
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants

19 Oct 2021 05:30:00 By Nasdaq GlobeNewswire
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

29 Sep 2021 05:30:00 By Nasdaq GlobeNewswire
Adagio Therapeutics to Participate in the Guggenheim 2nd Annual Vaccines & Infectious Day Conference

29 Sep 2021 05:30:00 By Nasdaq GlobeNewswire

<<
<
2
3
4
5
6
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.